<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294680</url>
  </required_header>
  <id_info>
    <org_study_id>BMH 19-29</org_study_id>
    <nct_id>NCT04294680</nct_id>
  </id_info>
  <brief_title>Opiate Sparing Versus Opiate Based Following Shoulder Arthroplasty</brief_title>
  <official_title>Prospective, Randomized, Controlled Trial of an Opiate Sparing Protocol Versus Standard Opiate-Based Protocol Following Shoulder Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campbell Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campbell Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the difference between an opiate sparing pain management protocol versus a&#xD;
      standard opiate-based protocol following shoulder arthroplasty in the ninety day&#xD;
      postoperative period regarding visual analog scores and oral morphine equivalents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, investigator initiated, prospective, randomized, controlled trial&#xD;
      conducted among patients who have given voluntary consent to participate. Participation will&#xD;
      last until the completion of the twelve weeks standard of care follow up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day one</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day two</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day three</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day four</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day five</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day six</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day seven</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day fourteen (two weeks)</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day forty two (six weeks)</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative day ninety (twelve weeks)</time_frame>
    <description>Patient reported pain score from zero to ten where zero is no pain and ten is the most pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Morphine Equivalents</measure>
    <time_frame>total of oral morphine equivalent in ninety day (twelve weeks) postoperative period</time_frame>
    <description>Calculated from opiate consumed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Opiate Sparing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryotherapy one hour daily four times per day for two weeks postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeproazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative Oxycodone 5 milligrams every six hours by mouth as needed for uncontrolled pain for fourteen days postoperative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opiate Based</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oxycodone 5 to 10 milligrams every four to six hours by mouth as needed for pain for fourteen days postoperative Acetaminophen 1000 milligrams every six hours by mouth for fourteen days postoperative Gabapentin 100 milligrams three times per day by mouth for thirty days postoperative Celecoxib 100 milligrams two times per day by mouth for thirty days postoperative Esomeprazole 20 milligrams daily by mouth for thirty days postoperative Ondansetron 4 milligrams every eight hours by mouth as needed for nausea and/or vomiting for fourteen days postoperative</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryotherapy</intervention_name>
    <description>see opiate sparing description</description>
    <arm_group_label>Opiate Sparing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary shoulder arthroplasty&#xD;
&#xD;
          -  18-85 years of age&#xD;
&#xD;
          -  Body Mass Index greater than or equal to 45&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Willing and able to cooperative in the required postoperative therapy&#xD;
&#xD;
          -  Willing and able to complete scheduled follow-up evaluations&#xD;
&#xD;
          -  Fluent in verbal and written English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years or over 85 years of age&#xD;
&#xD;
          -  Unable to provide written informed consent, cooperate with postoperative therapy, or&#xD;
             complete follow-up evaluations&#xD;
&#xD;
          -  Known sensitivity, allergy, or intolerance to medications with protocols&#xD;
&#xD;
          -  Renal disease as defined by active or impending dialysis within six months or kidney&#xD;
             transplant&#xD;
&#xD;
          -  Concomitant ipsilateral upper extremity injury or condition other than shoulder that&#xD;
             compromises function&#xD;
&#xD;
          -  Chronic pain syndrome&#xD;
&#xD;
          -  Five consecutive days of opiate use with the previous ninety days&#xD;
&#xD;
          -  Worker's compensation claim&#xD;
&#xD;
          -  Women who are pregnant, planning to become to become pregnant, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler Brolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campbell Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campbell Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campbell Clinic</investigator_affiliation>
    <investigator_full_name>Tyler J. Brolin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

